1. Home
  2. RYTM vs KD Comparison

RYTM vs KD Comparison

Compare RYTM & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • KD
  • Stock Information
  • Founded
  • RYTM 2008
  • KD 2020
  • Country
  • RYTM United States
  • KD United States
  • Employees
  • RYTM N/A
  • KD N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • KD EDP Services
  • Sector
  • RYTM Health Care
  • KD Technology
  • Exchange
  • RYTM Nasdaq
  • KD Nasdaq
  • Market Cap
  • RYTM 6.4B
  • KD 7.3B
  • IPO Year
  • RYTM 2017
  • KD N/A
  • Fundamental
  • Price
  • RYTM $97.86
  • KD $30.62
  • Analyst Decision
  • RYTM Strong Buy
  • KD Buy
  • Analyst Count
  • RYTM 13
  • KD 4
  • Target Price
  • RYTM $109.77
  • KD $42.00
  • AVG Volume (30 Days)
  • RYTM 627.7K
  • KD 2.2M
  • Earning Date
  • RYTM 11-04-2025
  • KD 11-05-2025
  • Dividend Yield
  • RYTM N/A
  • KD N/A
  • EPS Growth
  • RYTM N/A
  • KD N/A
  • EPS
  • RYTM N/A
  • KD 1.23
  • Revenue
  • RYTM $156,287,000.00
  • KD $15,061,000,000.00
  • Revenue This Year
  • RYTM $46.10
  • KD $6.91
  • Revenue Next Year
  • RYTM $60.39
  • KD $2.63
  • P/E Ratio
  • RYTM N/A
  • KD $24.97
  • Revenue Growth
  • RYTM 53.55
  • KD N/A
  • 52 Week Low
  • RYTM $45.91
  • KD $22.68
  • 52 Week High
  • RYTM $106.52
  • KD $44.20
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 49.11
  • KD 43.62
  • Support Level
  • RYTM $95.88
  • KD $28.97
  • Resistance Level
  • RYTM $102.79
  • KD $30.37
  • Average True Range (ATR)
  • RYTM 3.20
  • KD 0.83
  • MACD
  • RYTM -0.25
  • KD -0.01
  • Stochastic Oscillator
  • RYTM 32.99
  • KD 49.55

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

Share on Social Networks: